How to Pick a CDMO for Small Batch Injectables

Choosing a CDMO for small batch injectables is one of the harder decisions in sterile drug development. A contract development and manufacturing organisation (CDMO) that suits a large commodity campaign is often the wrong fit for a small, high-value sterile programme, where a single batch carries significant value and significant risk. This guide explains why small batch and high-value injectable programmes are hard to place, and how to assess a CDMO for injectable drug manufacturing on fit, flexibility, risk and regulatory readiness with confidence.

Why are small batch injectables so hard to place?

Small batch injectable manufacturing sits in an awkward gap. The programme is too small to attract a large CDMO optimised for high-volume campaigns, yet too complex and too regulated to hand to a generalist. Several factors make these products hard to place:

• Minimum batch sizes. Many sterile lines are built for large fills, so a small batch either does not fit the equipment or carries a high cost per unit.
• Changeover and scheduling. A short run still needs full aseptic set-up, cleaning and validation, which is hard to justify commercially on low volume.
• Value concentration. With high-value injectable drugs, a single failed batch can represent a large financial loss, so risk tolerance is very low.
• Complex formulations. Biologics, controlled substances and sensitive molecules need capabilities a generalist may not have.
• Regulatory weight. The product still has to meet the full sterile and good manufacturing practice (GMP) standard, whatever the batch size.

What makes small batch injectable programmes high-value and high-risk?

High-value injectable drugs concentrate a great deal of value into very few units. Early commercial launches, orphan indications, high-cost biologics and clinical supply for pivotal trials all share the same profile: the cost per unit is high, the volumes are low and the margin for error is small. That changes what good looks like in a manufacturing partner:

• A failed batch is expensive, so process robustness and a strong quality culture matter more than headline capacity.
• Sterility is non-negotiable, because the product is injected directly and there is no room for microbial or particulate risk.
• Supply continuity is critical, especially for orphan and clinical products where patients depend on a single source.
• Temperature-sensitive biologics need cold chain designed in from the start.

How to assess a CDMO for injectable drug manufacturing

When you evaluate a CDMO for injectable drug manufacturing, four dimensions matter most. Assess each deliberately rather than relying on a capability list:

Sterile manufacturing fit

Confirm the site runs the sterile technology your product needs, from aseptic fill-and-finish to lyophilisation, and that it can fill the container your product requires: vials, prefilled syringes or ampoules. Check that it handles your molecule class, including biologics and controlled substances.

Flexibility

Ask whether the site can run a small batch economically and still scale up later without a change of site. A wide batch range is what lets a product grow within the same equipment family.

Risk and reliability

Look at the track record, the available capacity, the quality culture and on-time delivery. Quality risk management under the International Council for Harmonisation should be visible in how the site works, not just in its documents.

Regulatory readiness

Verify GMP certification for the dosage form and an inspection history with the authorities of your target markets. Strong documentation and a robust quality system are what carry a small batch through audit and release.

Batch size and flexibility: why the low end matters

For small batch injectables, the bottom of a site’s range matters more than the top. A partner whose range covers both a small clinical or launch batch and a larger commercial batch lets a product grow without a costly technology transfer to a new site. Ask for the full range, not just the maximum, and confirm the site can run small-scale injectable batch production without penalising cost or quality.

Regulatory readiness for injectable outsourcing

Pharmaceutical outsourcing of a sterile injectable transfers the manufacturing, but not the accountability. The CDMO must meet the same standard your own site would. Confirm that it works to the sterile requirements of EU GMP Annex 1 and the current good manufacturing practice regulations, and check for:

• GMP certification for the specific dosage form.
• An inspection history with multiple international health authorities.
• A documented Contamination Control Strategy.
• Stability and release testing under recognised conditions.
• A quality system that supports deviations, change control and documentation.

A checklist for choosing a CDMO for small batch injectables

Use these questions to compare partners quickly:

• Does the batch range cover both your small launch volume and your future commercial target?
• Can it fill the sterile format your product needs: vials, prefilled syringes or ampoules?
• Does it handle your molecule class, including biologics and controlled substances?
• Is it GMP-certified and inspected by the authorities of your target markets?
• Can it support the product from clinical batches through to commercial supply?
• Is there a single point of contact and clear governance across the programme?

How Adragos supports small batch and high-value injectables

We are set up for the programmes that are hardest to place. Our integrated sterile network takes a product from clinical batches to commercial supply, combining aseptic fill-and-finish, lyophilisation, inspection and packaging. In practice that gives you:

• Clinical and small-scale commercial supply: good manufacturing practice batches for Phase I to III and production for clinical and small-scale commercial supply, so a small batch has a home.
• Complex molecules: complex formulations, aseptic compounding, biologics and controlled substances.
• Format choice: liquid and lyophilised vials, prefilled syringes and ampoules, with ampoule formulation from 30 litres to support smaller volumes.
• Clinical materials support: feasibility and preclinical materials, GMP manufacturing and secondary packaging or clinical kit preparation.
• Regulatory strength: GMP-certified sites audited by more than ten international health authorities, with support for regulated programmes in the United States.
• One partner across the journey: project management from feasibility to GMP production, with one point of contact, one governance and one quality mindset.

Our sterile network spans Jura in Switzerland, Maisons-Alfort in France, Livron in France and Kawagoe in Japan, covering vials, prefilled syringes and ampoules across clinical and commercial supply. To discuss a small batch or high-value injectable programme, contact our sterile manufacturing team.

Frequently asked questions

What is a small batch in injectable manufacturing?

A small batch is a low-volume sterile production run, typical of clinical supply, early commercial launch, orphan drugs and high-value biologics. There is no single threshold, because what counts as small depends on the equipment and the product.

Why do CDMOs struggle with small batch injectables?

Many sterile lines are designed for large fills, so a small batch may not fit the minimum size or may carry a high cost per unit once full aseptic set-up, cleaning and validation are taken into account.

What is a CDMO?

A CDMO is a contract development and manufacturing organisation, a partner that develops and manufactures a drug product on behalf of the company that owns it, including sterile injectables.

Can a small batch injectable scale up to commercial supply later?

Yes, if you choose a partner whose batch range covers both your small launch volume and your future commercial target, so the process can grow without a technology transfer to a new site.

What regulatory standards apply to outsourced sterile injectables?

Outsourced sterile injectables must meet good manufacturing practice, including the sterile requirements of Annex 1, and the site should have an inspection history with the health authorities of the target markets.